Journal of Contemporary Brachytherapy最新文献

{"title":"Inter-observer variation of target volume delineation for CT-guided cervical cancer brachytherapy.","authors":"Aysenur Elmali,&nbsp;Fatih Biltekin,&nbsp;Sezin Yuce Sari,&nbsp;Melis Gultekin,&nbsp;Deniz Yuce,&nbsp;Ferah Yildiz","doi":"10.5114/jcb.2023.131242","DOIUrl":"10.5114/jcb.2023.131242","url":null,"abstract":"<p><strong>Purpose: </strong>Delineation is a critical and challenging step in radiotherapy planning. Differences in delineation among observers are common, despite the presence of contouring guidelines. This study aimed to identify the inter-observer variability in the target volume delineation of computed tomography (CT)-guided brachytherapy for cervical cancer.</p><p><strong>Material and methods: </strong>Four radiation oncologists (ROs) with different expertise levels delineated high-risk (HR) and intermediate-risk (IR) clinical target volume (CTV) according to GYN GEC-ESTRO recommendations, in a blinded manner on every CT set of ten locally advanced cervical cancer cases. The most experienced RO's contours were determined as the index and used for comparison. Dice similarity coefficient (DSC) and pairwise Hausdorff distance (HD) metrics were applied to compare the overlap and gross deviations of all contours.</p><p><strong>Results: </strong>Median DSC for HR-CTV and IR-CTV were 0.73 and 0.76, respectively, and a good concordance was achieved for both in majority of contours. While there was no difference in DSC measurements for HR-CTV among the three ROs, RO-3 provided improved DSC values for IR-CTV (<i>p</i> = 0.01). Median HD95 was 5.02 mm and 6.83 mm, and median HDave was 1.69 mm and 2.21 mm for HR-CTV and IR-CTV, respectively. There was no significant difference among ROs in HR-CTV for HD95 or HDave; however, IR-CTV value was significantly improved according to RO-3 (<i>p</i> = 0.01). Case-by-case HD analysis showed no significant inter-observer variations, except for two cases.</p><p><strong>Conclusions: </strong>The inter-observer agreement is generally high for target volumes in CT-guided brachytherapy for cervical cancer. The agreement is lower for IR-CTV than HR-CTV. The individual characteristics of each case and different expertise levels of the ROs may have caused the differences. Despite the good concordance for delineation, dosimetric consequences can still be clinically significant.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":"15 4","pages":"253-260"},"PeriodicalIF":1.4,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/99/5d/JCB-15-51393.PMC10548424.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41172507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of doses to pelvic lymph node regions from image-guided high-dose-rate interstitial brachytherapy for carcinoma of the uterine cervix.","authors":"Ajeet Kumar Gandhi,&nbsp;Madhup Rastogi,&nbsp;Vachaspati Kumar Mishra,&nbsp;Anoop Kumar Srivastava,&nbsp;Farhana Khatoon,&nbsp;Daya Nand Sharma","doi":"10.5114/jcb.2023.130992","DOIUrl":"10.5114/jcb.2023.130992","url":null,"abstract":"<p><strong>Purpose: </strong>Interstitial brachytherapy (ISBT) is indicated for intact cervical carcinoma (IN-CC) if intracavitary brachytherapy (ICRT) is not feasible and also in vault carcinoma (VA-C). We aimed to evaluate the doses to pelvic lymph node regions in IN-CC and VA-C treated with ISBT.</p><p><strong>Material and methods: </strong>Ten patients (6 IN-CC, 4 VA-C) were chosen for this dosimetric study. IN-CC had a central tandem in addition to the needles. External iliac (EI-N), internal iliac (II-N), obturator (OB-N) and sacral (SA-N) groups of lymph nodes were delineated. A dose of 10 grays (Gy) and 8 Gy each × 2 fractions was prescribed to the target in IN-CC and VA-C respectively. Doses received by 100%, 90% and 50% volume (D₁₀₀, D₉₀, D₅₀) and D_2cc, D_1cc, D_0.1cc were evaluated. Doses to lymph nodal groups in IN-CC vs. VA-C were compared using Student's <i>t</i>-test.</p><p><strong>Results: </strong>For 20 implants, the median number of needles was 18 (range, 16-20). Mean D₉₀ and D_2cc of the combined bilateral OB-N, II-N, EI-N and SA-N groups were 33.62 ±3.46% and 102.94 ±10.71%, 6.98 ±0.65% and 39.69 ±3.64%, 5.1 ±0.51% and 15.4 ±0.8%, 7.76 ±0.95% and 15.36 ±1.09% of the prescribed doses respectively. Patients with a central tandem (IN-CC) received significantly higher doses to external, internal iliac and sacral group of lymph nodes (<i>p</i> < 0.001) as compared to VA-C.</p><p><strong>Conclusions: </strong>In patients with cervical carcinoma treated with ISBT, pelvic lymph node groups received significant doses. The dose contribution to pelvic lymph nodes is higher in patients with intact cervical cancer where a central tandem is used as compared to post-operative patients.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":"15 4","pages":"261-268"},"PeriodicalIF":1.4,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/88/fe/JCB-15-51350.PMC10548423.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41169112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncologic outcomes after MRI-assisted image-guided brachytherapy with hybrid interstitial and intra-cavitary applicators under moderate sedation for locally advanced cervix cancer.","authors":"Kiattisa Sommat,&nbsp;Swee Peng Yap,&nbsp;Richard Ming Chert Yeo,&nbsp;Hoon Seng Khoo Tan,&nbsp;Yoke Lim Soong,&nbsp;Jeffrey Kit Loong Tuan,&nbsp;Iris Huili Sin","doi":"10.5114/jcb.2023.130976","DOIUrl":"10.5114/jcb.2023.130976","url":null,"abstract":"<p><strong>Purpose: </strong>To report outcomes of using image-guided hybrid intra-cavitary/interstitial applicators under moderate sedation for locally advanced cervical cancer patients in our institution.</p><p><strong>Material and methods: </strong>A total of 69 fractions of brachytherapy with hybrid applicators were performed in 33 patients from January 2017 to April 2021. All patients underwent MRI pelvis 1 week pre-brachytherapy to determine suitability for interstitial brachytherapy and pre-plan needle placement. All insertion of applicators were performed under moderate sedation with midazolam and/or fentanyl. Fifty-eight (84.1%) fractions were planned with CT alone. Clinical outcomes, dose volume parameters, and toxicities were analyzed.</p><p><strong>Results: </strong>The median follow-up was 28 months. A total of 320 needles (median, 5 needles per fraction) were implanted, with a median insertion depth of 3 cm (range, 1.5-4 cm). The median high-risk clinical target volume (HR-CTV) during initial brachytherapy was 34.5 cc (range, 17.8-74.7 cc). The median total EQD₂ D_2cc of the rectum, bladder, sigmoid, and small intestine colon was 71.8 Gy, 81.5 Gy, 69 Gy, and 58.3 Gy, respectively. The 2-year local control and overall survival were 80.7% and 77.7%, respectively. Larger volume HR-CTV was significantly associated with worse local control (HR = 1.08, <i>p</i> = 0.005) and overall survival (HR = 1.04, <i>p</i> = 0.015). None of the patients required in-patient admission or blood transfusion post-procedure. Late grade 3 gastrointestinal and genitourinary toxicities were observed in 4 patients (12.2%).</p><p><strong>Conclusions: </strong>Hybrid applicators inserted under moderate sedation are feasible and safe. Image-guided interstitial brachytherapy with CT planning aided by MRI performed 1 week pre-brachytherapy is associated with favorable outcomes and modest toxicities.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":"15 4","pages":"245-252"},"PeriodicalIF":1.4,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4a/95/JCB-15-51344.PMC10548430.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41157553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced non-melanoma skin cancer in elderly patients: When surgery says NO, interventional radiotherapy (brachytherapy) says YES.","authors":"Adam Chicheł,&nbsp;Artur J Chyrek,&nbsp;Adam Kluska,&nbsp;Wojciech M Burchardt","doi":"10.5114/jcb.2023.130715","DOIUrl":"10.5114/jcb.2023.130715","url":null,"abstract":"<p><strong>Purpose: </strong>The prevalence of non-melanoma skin cancer (NMSC) increases, especially in older adults with comorbidities, narrowing radical treatment options. About 5% of skin cancer patients are diagnosed with an advanced stage, which impairs daily functioning. The study was to present a retrospective summary of elderly patients unfit for surgery and treated with various brachytherapy (BT) techniques tailored individually for locally advanced NMSCs in a reference BT department. Clinical case presentations supported the findings.</p><p><strong>Material and methods: </strong>Inoperable patients older than 75 years presenting with advanced pathologically confirmed NMSCs were retrospectively identified. All cases were individually assessed, and the best suiting radical treatment option was chosen, including contact, interstitial, or hybrid high-dose-rate (HDR) or pulsed-dose-rate (PDR) BT. Doses ranging from 45 to 60 Gy were administered to clinical target volume (CTV) in different time schedules. All patients were closely followed-up until complete remission.</p><p><strong>Results: </strong>Ten elderly patients (mean age, 84 years) with differently located locally advanced NMSCs (all staged T3) were treated between 2007 and 2022. Six basal and four squamous cell carcinoma cases showed most painful symptoms as well as bleeding and exudation. Six patients underwent HDR-BT and four PDR-BT. Six patients had superficial, and four interstitial or hybrid applications. All patients completed the intended protocols. Median follow-up was 8.5 months (range, 3-35 months). Six out of ten patients died from other reasons before analysis. All case data were presented in the text and respective figures.</p><p><strong>Conclusions: </strong>Advanced NMSCs in elderly patients are challenging in terms of cure. Inoperable cases may be referred for feasible and locally effective interventional radiotherapy (BT). Individually tailored BT leads to an excellent disease control, function sparing, symptoms release, and quality of life improvement. Large treated volumes are related to prolonged healing. BT should be discussed in a multidisciplinary tumor board regarding older patients with symptomatic functions affecting advanced NMSCs.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":"15 4","pages":"235-244"},"PeriodicalIF":1.4,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e2/19/JCB-15-51298.PMC10548428.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41158079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The application of 3D brachytherapy in cervical stump cancer: A retrospective study.","authors":"Yuxuan Wang,&nbsp;Xue Qin,&nbsp;Lang Yu,&nbsp;Xiaorong Hou,&nbsp;Ke Hu,&nbsp;Junfang Yan,&nbsp;Fuquan Zhang","doi":"10.5114/jcb.2023.130898","DOIUrl":"10.5114/jcb.2023.130898","url":null,"abstract":"<p><strong>Purpose: </strong>Cervical stump cancer is a carcinoma that grows on the cervical stump after a sub-total hysterectomy. There have been no studies on the application of 3D brachytherapy in cervical stump cancer. In the present study, we aimed to compare the curative effects, toxicity, and dosimetry of 3D and 2D brachytherapy in cervical stump cancer.</p><p><strong>Material and methods: </strong>Thirty-one patients admitted between 2012 and 2021, who were concurrently treated with intensity-modulated radiation therapy and brachytherapy for cervical stump cancer were divided into three groups according to the brachytherapy techniques: 2D brachytherapy, 3D image-guided brachytherapy (3D-IGBT), and 2D + 3D. For patients undergoing 2D brachytherapy and 3D-IGBT, data on survival, complications, and dose to target area or organs at risk (OARs) were collected and compared. Furthermore, dosimetry difference was investigated by reconstructing the 2D plan into a 3D plan.</p><p><strong>Results: </strong>The median follow-up duration of all patients was 58 months. The overall 5-year progression-free survival, overall survival, and local control rates were 69.6%, 90.2%, and 78.2%, respectively. Late complications in the rectum, sigmoid colon, and bladder were milder in 3D brachytherapy than in 2D brachytherapy. Concerning the D₉₀ value of clinical target volume (CTV) and D_2cm³ value of OARs in EQD₂, the 3D brachytherapy provided a lower dose to CTV (76.5 Gy vs. 95.9 Gy, on average) and OARs compared with 2D brachytherapy.</p><p><strong>Conclusions: </strong>Despite lacking statistical significance, 3D brachytherapy showed better outcomes regarding late toxicity than 2D brachytherapy, owing to the lower dose coverage in the bladder, rectum, sigmoid colon, and small intestine.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":"15 4","pages":"275-282"},"PeriodicalIF":1.4,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c7/df/JCB-15-51339.PMC10548426.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41173450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TACE combined with portal particle implantation in a case of stage IIIa primary hepatocellular carcinoma treated with sequential anlotinib.","authors":"Cheng Lin,&nbsp;Chen Chen,&nbsp;Guiliu Huang,&nbsp;Yueyong Li,&nbsp;Lifeng Zhao,&nbsp;Zhongheng Wei","doi":"10.5114/jcb.2023.131239","DOIUrl":"10.5114/jcb.2023.131239","url":null,"abstract":"<p><p>Few cases of patients with Cheng's type III portal vein tumor thrombus (PVTT) have been reported to achieve radical cure without recurrence over time. In this study, we reported on a 55-year-old male patient with a diagnosis of stage IIIa China liver cancer staging (CNLC), PVTT Cheng's type III, mild cirrhosis, and chronic viral hepatitis B. TACE combined with radioactive iodine-125 (¹²⁵I) particle implantation was applied to achieve radical treatment with sequential oral anlotinib hydrochloride capsules. This case might serve as a reference for the treatment of this disease.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":"15 4","pages":"283-289"},"PeriodicalIF":1.4,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/c0/JCB-15-51391.PMC10548425.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41155750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intra-luminal iodine-125 brachytherapy in patients with esophageal carcinoma and 3/4 dysphagia score: A feasibility study.","authors":"Kaihao Xu,&nbsp;Chuan Tian,&nbsp;Yahua Li,&nbsp;Yiming Liu,&nbsp;Jianzhuang Ren,&nbsp;Xinwei Han,&nbsp;Dechao Jiao","doi":"10.5114/jcb.2023.127857","DOIUrl":"https://doi.org/10.5114/jcb.2023.127857","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the clinical results of nasal feeding nutritional tube (NFNT)-loaded iodine-125 (¹²⁵I) seeds in intra-luminal brachytherapy (ILBT) for esophageal carcinoma (EC) patients with a 3/4 dysphagia score.</p><p><strong>Material and methods: </strong>From January 2019 to January 2020, 26 patients (female/male: 17/9, mean age: 75.3 years, dysphagia score 3/4: 6/20, mean Karnofsky score: 58.4) with EC underwent NFNT-loaded ¹²⁵I seed placement for both nutrition and brachytherapy. Technical and clinical success, D₉₀ (radiation dose received by 90% of tumor volume) and organ at risk (OAR) dose, complications, dysphagia-free time (DFT), and overall survival (OS) time were documented. Local tumor diameter, Karnofsky score, dysphagia score, and quality of life (QoL) were compared before and 6 weeks after tube placement.</p><p><strong>Results: </strong>Technical and clinical success rates were 100% and 76.9%, respectively. The D₉₀ and OAR doses were 39.7 Gy and 2.3 Gy, respectively. Eight cases (30.8%) experienced mild complications, but no seed loss, fistula, and massive bleeding were observed. Median DFT and OS were 3.1 months and 13.7 months, respectively. Tumor diameter and dysphagia score significantly decreased (<i>p</i> < 0.05), Karnofsky score significantly improved (<i>p</i> < 0.05), and QoL scores related to physical function, physical functioning, general health, vitality, and emotional functioning improved (<i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>NFNT-loaded ¹²⁵I brachytherapy for ILBT is technically a safe and effective strategy for EC patients with low Karnofsky scores, and can be a bridging therapy for advanced anti-cancer treatment.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":"15 3","pages":"166-173"},"PeriodicalIF":1.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e1/44/JCB-15-50789.PMC10324586.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9810120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multilayer intensity modulated contact interventional radiotherapy (brachytherapy): Stretching the therapeutic window in skin cancer.","authors":"Bruno Fionda,&nbsp;Elisa Placidi,&nbsp;Enrico Rosa,&nbsp;Valentina Lancellotta,&nbsp;Gerardina Stimato,&nbsp;Martina De Angeli,&nbsp;Francesco Giuseppe Ciardo,&nbsp;Patrizia Cornacchione,&nbsp;Frank-Andre Siebert,&nbsp;Luca Tagliaferri,&nbsp;Luca Indovina","doi":"10.5114/jcb.2023.127837","DOIUrl":"https://doi.org/10.5114/jcb.2023.127837","url":null,"abstract":"<p><p>Interventional radiotherapy (IRT, brachytherapy) is a highly effective treatment method for non-melanoma skin cancer (NMSC). Traditionally, the maximum depth of NMSC lesions considered eligible for contact IRT was 5 mm; however, following several national surveys and recent recommendations, such cut-off, lesions thicker than 5 mm may be treated by contact IRT. The use of image guidance in defining the actual depth in treating NMSC to correctly identify clinical target volume (CTV) and prevent unnecessary toxicity is of paramount importance. The aim of the paper was to describe a multilayer arrangement of catheters to treat NMSC lesions thicker than 5 mm, thus proposing an example of dynamic intensity modulated IRT, using different catheter-to-skin distance of sources to reach the best CTV coverage and maximally reduce the excess of dose to the skin.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":"15 3","pages":"220-223"},"PeriodicalIF":1.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/37/0a/JCB-15-50784.PMC10324588.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10186439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ophthalmic applicator displacement as a method of treating large diffuse uveal melanomas.","authors":"Anna Markiewicz,&nbsp;Konrad Skórkiewicz,&nbsp;Agata Bogdał,&nbsp;Dominik Medoń,&nbsp;Mirella Świder,&nbsp;Elz Bieta Korab-Chrzanowska,&nbsp;Joanna Kowal,&nbsp;Magdalena Dębicka-Kumela,&nbsp;Bożena Romanowska-Dixon","doi":"10.5114/jcb.2023.128920","DOIUrl":"https://doi.org/10.5114/jcb.2023.128920","url":null,"abstract":"<p><strong>Purpose: </strong>The presentation of results of an ophthalmic plaque displacement as a brachytherapy treatment method of large diffuse uveal melanomas.</p><p><strong>Material and methods: </strong>This was a retrospective analysis of treatment results of 9 patients with large diffuse uveal melanomas using ophthalmic plaque displacement. Patients were treated with this method in our center between 2012 and 2021 (last follow-up visit in 2023). To achieve appropriate radiation dose distribution for large tumors with a base greater than 18 mm, brachytherapy (¹⁰⁶Ru in 7 patients and ¹²⁵I in 2 patients) with applicator displacement was used as primary treatment. Median follow-up was 2.9 years, and for patients with positive primary treatment results, it was 1.7 months. Median time to local relapse was 2.3 years.</p><p><strong>Results: </strong>In 5 patients, a positive result of local treatment was obtained, out of whom, one patient underwent enucleation due to complications. In the next 4 cases, local recurrence developed. In all tumors, the use of applicator displacement method caused that planning target volume (PTV) was effectively covered with treatment isodose.</p><p><strong>Conclusions: </strong>Brachytherapy with ocular applicator displacement allows for the treatment of tumors with base measurements larger than 18 mm. The application of this method may be considered as an alternative for eye enucleation in particular cases of large diffuse tumors, such as a neoplasm of the eye with vison, or when a patient does not consent to enucleation.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":"15 3","pages":"184-190"},"PeriodicalIF":1.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/08/b3/JCB-15-50907.PMC10324590.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10186445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of dermatofibrosarcoma protuberans of the scalp treated with surface mould brachytherapy.","authors":"Raj Hans,&nbsp;Sankalp Singh,&nbsp;Prince Arvind,&nbsp;Arti Sarin,&nbsp;Manoj K Semwal,&nbsp;Pankaj Vats","doi":"10.5114/jcb.2023.127807","DOIUrl":"https://doi.org/10.5114/jcb.2023.127807","url":null,"abstract":"<p><p>Dermatofibrosarcoma protuberans (DFSP) is a locally aggressive soft tissue tumor with a high propensity of local recurrence after surgery. Radiotherapy as an adjuvant therapy has been shown to reduce recurrent rates of this disease. Surface mould brachytherapy is an effective and safe modality for the delivery of radiotherapy in soft tissue tumors, though its utilization and popularity have decreased in recent years. Here, we presented a case of a recurrent DFSP of the scalp who was treated with surgery followed by adjuvant surface mould brachytherapy to avoid dose inhomogeneity likely to occur in this anatomic region with external beam radiotherapy in the absence of intensity-modulated radiotherapy. The treatment was delivered successfully with minimal adverse reactions, and the patient is disease-free at 18 months post-treatment with no treatment toxicity.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":"15 3","pages":"224-228"},"PeriodicalIF":1.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5a/07/JCB-15-50776.PMC10324587.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10167689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}